Kirk's Market Thoughts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts

COHR 191.91

+0.5%

Dec 23 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kirk © who wrote (11775)	8/23/2021 7:11:53 AM
From: w0z	Read Replies (1) of 26834

This study had a 100% success rate (nobody died) while the Placebo had the standard just under 2% death rate While encouraging this trial seems flawed. 1. They are only dosing Ivermectin at 6 mg per day which is approximately half what the FLCCC recommends for prophylaxis, and well below what they recommend for early outpatient (positive diagnosis) treatment. The dosage should be based on body weight (200 micrograms per kg of body weight) which works out to around 12 mg for a 120 pound person (my assumption for Bangladeshis). Early outpatient should be 2-3X the prophylaxis treatment. 2. There is NO mention of zinc supplementation (30-40 mg/day). All of the zinc ionophores (e.g. Quercetin, Hydorxychloroquine, and Ivermectin) work to facilitate absorption of zinc into the tissues, so having one without the other seems to miss the point. Zinc is apparently what gives tissues protection from covid. I really don't understand why there are so many flawed trials (this is not the first I've heard of that omitted zinc). Anyway it's encouraging that there were no deaths in spite of the above.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next